Predicting polycystic ovary syndrome (PCOS) with machine learning algorithms from electronic

health records

Zahra Zad, BS[1*]; Victoria S. Jiang, MD[2*]; Amber T. Wolf, BA[3]; Taiyao Wang, PhD[1]; Jay Jojo Cheng,

BA[4]; Ioannis Ch. Paschalidis, PhD[1,5]; Shruthi Mahalingaiah, MD, MS[2,6~]

[1]Division of Systems Engineering, Center for Information and Systems Engineering (CISE), Boston

University, 15 St. Mary's Street, Brookline, MA 02446, USA

[2]Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology,

Massachusetts General Hospital, 55 Fruit Street, Yawkey 10, Boston, MA 02114, USA

[3]Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA

[4] Department of Biostatistics and Medical Informatics, University of Wisconsin, West Johnson Street,

Madison, WI 53792, USA

[5]Department of Electrical & Computer Engineering, Department of Biomedical Engineering, and Faculty

for Computing & Data Sciences, Boston University, 8 St. Mary's Street, Boston, MA 02215, USA

[6]Department of Environmental Health, Harvard T.H. Chan School of Public Health, 665 Huntington

Avenue, Boston, MA 02115, USA

* Zahra Zad and Victoria S. Jiang contributed equally to this manuscript and are co-first authors of this

manuscript.

Keywords: Polycystic ovary syndrome (PCOS), disease prediction, predictive analytics, machine

learning.

˜Corresponding Author & reprint requests:

Shruthi Mahalingaiah, MD, MS. **ORCID: 0000-0002-5527-5787**

Email: shruthi@hsph.harvard.edu

Study funding/competing interest(s): This study was partially supported by National Science

Foundation grants CCF-2200052, IIS-1914792, and DMS-1664644, by the NIH under grants R01

GM135930 and UL54 TR004130, and by the Boston University Kilachand Fund for Integrated Life

Science and Engineering

Disclosure Summary: The authors declare no conflict of interest and nothing to disclose.

Structured Abstract

Context. Predictive models have been used to aid early diagnosis of PCOS, though existing models are

limited to fertility clinic populations.

Objective. Build a predictive model based on an outpatient population at risk for PCOS to facilitate

earlier diagnosis and risk prediction.

Design. Retrospective cohort study from a SafetyNet hospital's electronic medical records (EMR) from

2003-2016.

Setting. Hospital outpatient clinics

Patients or Other Participants. 30,601 women aged 18-45 years without concurrent endocrinopathy

who had any visit to Boston Medical Center for primary care, obstetrics/gynecology, endocrinology,

family medicine, or general internal medicine.

Intervention(s). None

Main Outcome Measure(s). Four prediction outcomes based on Rotterdam criteria using ICD-9 codes

for PCOS, irregular menstruation, hyperandrogenism, and PCOM on ultrasound.

Results. We developed predictive models using four machine learning methods: logistic regression,

supported vector machine, gradient boosted trees, and random forests. Hormone values (FSH, LH,

estradiol, and SHBG) were combined to create a multilayer perceptron score using a neural network

classifier. Prediction of PCOS prior to clinical diagnosis in an out-of-sample test set of patients achieved

AUC of 85%, 81%, 80%, 82%, respectively in Models I, II, III and IV. Significant positive predictors of

PCOS diagnosis across models included hormone levels and obesity; negative predictors included

gravidity and positive bHCG.

Conclusions. Among an at-risk population, machine learning algorithms were used to predict PCOS. This

approach may guide early detection of PCOS within EMR-interfaced populations to facilitate counseling

and interventions that may reduce long-term health consequences, however, additional studies including

an entire health system patient population are necessary for model validation.

Introduction

Polycystic ovary syndrome (PCOS) is the most common type of ovulation disorder and endocrinopathy among reproductive age women. PCOS is a diagnosis of exclusion after other endocrinopathies known to affect ovulation have been evaluated including thyroid, adrenal, and pituitary related disease. Based on the Rotterdam criteria, PCOS is diagnosed when two of the three following criteria are exhibited: clinical or biochemical hyperandrogenism, oligo-anovulation, and polycystic ovary morphology (PCOM) on transvaginal or transabdominal ultrasound. PCOS has a population prevalence of 5-15%, depending on the diagnostic criteria used (1).

PCOS is associated with multiple health issues and increased morbidity and mortality, including a high chronic disease burden that is also very costly for individuals with PCOS and insurers (2). PCOS is the leading cause of anovulatory infertility in reproductive-aged women. In fact, over 90% of anovulatory women who present to infertility clinics have PCOS (3). PCOS patients have an increased risk of endometrial hyperplasia and endometrial cancer (4) due to anovulatory cycles leading to long periods of exposure to the effects of unopposed estrogen. PCOS has been associated with the development of metabolic syndrome (5), diabetes (6), cerebrovascular disease and hypertension (7), compared to women without PCOS. Despite these serious health consequences, PCOS frequently goes undiagnosed due to the wide range of symptom severity on presentation, leading to delayed treatment and potentially more severe clinical sequelae due to lack of preventive care, health management, and counseling (4).

Predictive models can play a significant role in aiding earlier diagnosis of PCOS, though several include only those women presenting for fertility care. One model used serum anti-Müllerian hormone (AMH) and androstenedione levels, menstrual cycle length, and BMI to predict the development of PCOS in Chinese women (8). Another model used only AMH and BMI to predict a diagnosis of PCOS or other ovulatory dysfunction disorders (9). Other studies have created predictive models for certain outcomes among women with PCOS such as pregnancy outcomes (10,11) and insulin resistance (12). In this study, we use clinical and socioeconomic predictive variables among 30,601 women aged 18 to 45 years who

had testing/clinical findings that may facilitate a diagnosis of PCOS to develop and evaluate methods for

systematic identification of PCOS using existing electronic health records (EHR) data with the ultimate

goal of earlier detection and treatment of PCOS for improved long-term health outcomes.

Materials/Methods

Data acquisition

The dataset was created by querying de-identified patient data from female patients aged 18 to 45

years who had or were considered at risk for PCOS diagnosis by having had any one of the three testing

procedures for PCOS in their EHR. Included within the initial sample were those patients who had any

visit to Boston Medical Center (BMC) for primary care, obstetrics and gynecology, endocrinology, family

medicine, or general internal medicine and received: 1) a pelvic/transvaginal ultrasound for any reason, 2)

androgen lab assessment, or had clinical symptoms of androgen excess, 3) an ICD-9 label for irregular

periods, or 4) a PCOS diagnosis, between October 2003 to December 2016 within the BMC Clinical Data

Warehouse (CDW). The start-date was selected to reflect the first day that ICD-9 codes were used and

recorded at BMC. The end date reflected cessation of use of the ICD-9 codes and transition to ICD-10

codes within BMC. Exclusion criteria included diagnosis of concurrent endocrinopathy, such as thyroid

disorders, hyperaldosteronism, Cushing's syndrome, other adrenal gland disorders, or malignancy based

on ICD-9 codes as listed in Supplementary Table 1.

Ethical approval

The study was approved by the Institutional Review Board of Boston University School of

Medicine and the Harvard T.H. Chan School of Public Health (Protocol # H35708) and is considered

non-human subjects research.

Reference label definitions

Individual predictors

Time-varying predictor variables with a date stamp before that of the outcome of interest were

included in our models. We considered the following predictor variables:

Socioeconomic and lifestyle demographic variables: age, race (White/Caucasian, Black/African

American, Hispanic/Latina, Asian, Native Hawaiian/Pacific Islander, Middle Eastern, Other/Unknown),

smoking status (yes/no), marital status (single, married, separated, divorced, widowed, other),

homelessness (yes/no), and highest level of education (8th grade or less, some high school, high school

graduate, some college/technical/vocational training, graduated college/technical school/vocational

training, declined to answer, other).

Anthropometrics: Body mass index (BMI, kg/m^2) was either calculated from height and weight or

abstracted as the listed BMI variable associated with each visit. BMI was then categorized into three

categories: normal (BMI < 25 kg/m^2); overweight (BMI between 25-30 kg/m^2); and obese (BMI > 30

kg/m^2). To further capture the obesity population in the absence of height/weight/BMI data, the obese

category also included any patient with an ICD-9 code for unspecified obesity (278.00), morbid obesity

(278.01), localized adiposity (278.1), and/or a history of gastric bypass.

Cardiovascular health: To include blood pressure as a predictor variable, we defined a

categorical hypertension variable by using systolic (SBP) and diastolic (DBP) blood pressure readings

and ICD-9 diagnostic codes for unspecified essential hypertension (401.9), benign essential hypertension

(401.1), and essential primary hypertension (401.0). Blood pressure was categorized into three groups:

normal, defined by no ICD-9 codes for hypertension recorded and SBP < 120 mmHg, and DBP < 80

mmHg; elevated, defined by no ICD-9 codes for hypertension recorded and SBP was 120-129 mmHg or

DBP < 80 mmHg; hypertension, defined by any ICD-9 code for hypertension recorded or SBP $\geq$ 140

mmHg or DBP $\geq$ 90 mmHg.

Reproductive endocrine predictive variables: beta human chorionic gonadotropin (bHCG) level

(negative bHCG < 5 mIU/mL, positive bHCG $\geq$ 5 mIU/mL), HIV status (negative/positive), age at

menarche, pelvic inflammatory disease diagnosis (614.9), history of hysterosalpingogram, and gravidity

(history of present or prior pregnancy within obstetric history). Endocrine and metabolic lab values

included: TSH, glycosylated hemoglobin (A1c) as a marker for diabetes, low-density lipoprotein (LDL),

high density lipoprotein (HDL), and diagnosis of hypercholesterolemia (272.0).

Combined predictors

Expecting a nonlinear relationship between many reproductive hormones and a PCOS diagnosis,

we used a multilayer perceptron (MLP) neural network to map follicle-stimulating hormone (FSH),

luteinizing hormone (LH), sex hormone binding globulin (SHBG), and estradiol (E2) values to a

composite metric we call MLP score. The MLP score was repetitively trained and the hyperparameters

were tuned to generate a predictive probability associated with PCOS diagnosis for each predictive

model, as described with further detail below.

Outcomes

Defining PCOS: PCOS diagnosis was assigned for any patient who had an ICD-9 code for PCOS

(256.4) or met the Rotterdam criteria (13), according to which a positive diagnosis is made in the

presence of two out of the following three features: (i) irregular menses (IM) as defined by rare menses,

oligo-ovulation, or anovulation; (ii) hyperandrogenism (HA) as defined by clinical or biochemical

androgen excess; and (iii) polycystic ovarian morphology (PCOM) noted on transabdominal or

transvaginal ultrasound. Based on these three criteria, we defined three auxiliary variables IM, HA, and

PCOM to use in the definition of our labels. PCOM was captured through diagnostic radiology text

reports from ovarian ultrasound imaging for the subset that had ultrasound imaging (14).

Defining Irregular Menstruation (IM): IM was defined with the following ICD-9 codes: absence

of menstruation (626.0), scanty or infrequent menstruation (626.1), irregular menstrual cycle (626.4),

unspecified disorders of menstruation and abnormal bleeding from female genital tract (626.9), and

infertility, female associated with anovulation (628.0) (3).

Defining Hyperandrogenism (HA): HA was assigned to a patient if any of the androgen lab

testing for bioavailable testosterone, free testosterone, or total testosterone was greater than clinical

thresholds of 11 ng/dL, 5 pg/mL, 45 ng/dL, respectively. In addition, HA was assigned if ICD-9 codes

for hirsutism (704.1) or acne (706.1 or 706.0) were recorded for a patient.

Defining Ultrasound characteristics for polycystic ovarian morphology (PCOM): Among those

with an ultrasound in this dataset, PCOM was identified on ultrasound reports using natural language

processing (NLP) with complete methods detailed by Cheng and Mahalingaiah (14), to report PCOM as

identified (PCOM present), unidentified (PCOM absent), or indeterminate (PCOM unidentifiable based

on source report data).

We considered four models to predict the following: **Model I**: patients with ICD-9 diagnosis of

PCOS (256.4) within the EHR; **Model II**: patients diagnosed with PCOS by Rotterdam criteria having IM

and HA without a specific ICD-9 PCOS code; **Model III**: patients diagnosed with PCOS by Rotterdam

criteria having two out of the three conditions IM/HA/PCOM and without a specific ICD-9 PCOS code;

Model IV: all patients with PCOS using either Model I or Model III criteria. ICD-9 codes were abstracted

from the billing code and diagnosis code associated with each encounter within the EHR. Model I

included all patients who were diagnosed with PCOS. Model II and its superset Model III was composed

of patients who did not have a PCOS diagnosis code but met diagnostic criteria of PCOS based on

Rotterdam criteria, representing the patient population with undiagnosed PCOS. Model IV essentially

captures all women who were diagnosed or met criteria for PCOS within our population. Supplementary

Table 2 details model definitions and includes the count and percent of patients in each category. The date

of diagnosis was assigned by the date of PCOS ICD-9 code (256.4) for Model I, the date of the latest

diagnostic criteria met for Model II and III, and the earlier date associated with Model I and Model III, for

Model IV.

Predictive models

Classification methods

We explored a variety of supervised classification methods, both linear and nonlinear. Linear

methods included logistic regression (LR) and support vector machines (SVM) (15) and were fitted with

an additional regularization term: an L1-norm of the coefficient vector to inject robustness (16) and

induce sparsity. Regularization added a penalty to the objective function, thereby minimizing the sum of a

metric capturing fitness to the data and a penalty term that is equal to some multiple of a norm of the

model parameters. Sparsity was motivated by the earlier works (17–20), where it was shown that sparse

classifiers can perform almost as well as very sophisticated classification methods. Nonlinear methods,

including gradient boosted trees (GBT/XGBoost) (21) and random forests (RF) (22) which produce large

ensembles of decision trees, may yield better classification performance, but are not interpretable or

explainable to enable a safety check by a clinician. Specifically, the RF is a large collection of decision

trees and it classifies by averaging the decisions of these trees. The GBT/XGBoost, also called gradient

boosting machine (GBM), similarly combines decisions by many decision trees. We used LightGBM

which is a fast, high-performance GBM framework (23). We tuned GBM's hyperparameters through

cross-validation.

Performance metrics

To assess model performance, we obtained the Receiver Operating Characteristic (ROC) curve.

The ROC is created by plotting the true positive rate, which is indicative of sensitivity or recall, against

the false positive rate (equal to one minus specificity) at various thresholds. The c-statistic or the area

under the ROC curve (AUC), is used to evaluate the prediction performance. A perfect predictor is

defined by generating an AUC score of 1, and a predictor which makes random guesses has an AUC

score of 0.5. We also used the weighted-F1 score to evaluate the models. The weighted-F1 score is the

average of the F1 scores of each class weighted by the number of participants in each class. The class-

specific F1 scores are computed as the harmonic mean of precision and recall of a classifier which

predicts the label of the given class. The weighted-F1 score is between 0 to 1, and a higher value

represents a better model. The AUC is more easily interpretable, and the weighted F1-score is more

robust to class imbalance (24).

Statistical feature selection (SFS)

Categorical variables were converted into dummy/indicator variables. To avoid collinearity, we

dropped the missing or unclassified data (NaN) category. For continuous variables, missing values were

imputed by the median value for that variable. A summary of the missing variables for each model is

provided in Supplementary Table 3. Variables with very low variability (SD<0.0001) were assessed for

removal from the models, however none were noted in any model. We applied statistical feature selection

(SFS) to reduce the less informative features and simplify the models. For each of the four models'

outcomes, the chi-squared test was applied for binary variables and the Kolmogorov-Smirnov statistic for

continuous variables; the variables for which we could not reject the null hypothesis of the same

distribution for each class (p-value >0.01) were removed. Representative aggregated patient-level

statistics for each model are shown in Supplementary Table 4. We also removed one from each pair of

highly correlated variables (with absolute value of the correlation coefficient > 0.8) to avoid redundant

variables. Highly correlated variables and the retained variable are provided in Supplementary Table 5.

For all models we standardized the corresponding features by subtracting the mean and scaling to unit

variance.

Training-test splitting

232 We split the dataset into five random parts, where four parts were used as the training set, and the

233 remaining part was used for testing. We used the training set to tune the model hyperparameters via 5-fold

234 cross-validation, and we evaluated the performance metrics on the testing set. We repeated training and

235 testing five times, each time with a different random split into training/test sets. The mean and standard

236 deviation of the metrics on the test sets over the five repetitions are reported.

Development of the MLP score

For every model, there was a considerable difference between the AUC of linear models and non-

linear models. To improve the performance of our linear models, we utilized nonlinear models to capture

intricate relationships between features. We utilized Gradient Boosted Trees (GBT) to find which features

most commonly appeared together among decision trees. We found FSH, LH, SHBG, and estradiol levels

to be a meaningful group of features which are all reproductive hormones and continuous variables that

appeared together among trees for all our models. We subsequently used these four features as input

features into a multilayer perceptron (MLP) neural network model with three hidden layers, each

employing the rectified linear unit (ReLU) activation function. The neural network was trained using the

training set to classify PCOS. We used the output probability of the MLP model, which we called "MLP

score," as a new feature into our original predictive models.

Recursive feature elimination (RFE)

We also used a recursive feature elimination approach with L1-penalized logistic regression (L1-

regularized RFE) to extract the most informative features and develop parsimonious models. Specifically,

after running the L1-penalized logistic regression (L1-LR), we obtained weights associated with the

variables (i.e., the coefficients of the model, denoted by β), and we eliminated the variable with the

smallest absolute weight in each turn. We iterated in this fashion, eliminating one variable at a time, to

select a model that maximizes a metric equal to the mean AUC minus the standard deviation (SD) of the

AUC in a validation dataset (using 5-fold cross-validation on the training set to obtain an average of this

metric over five repetitions).

Final predictive models

We computed the performance of the following models: L1-penalized logistic regression (LR-

L1), support vector machine (SVM-L1), random forests (RF), and gradient boosted trees

(GBT/XGBoost). We calculated each variable's LR coefficient with a 95% confidence interval (β

[95%CI]), the correlation of the variable with the outcome (Y-correlation), the p-value of each variable

(p-value), the mean of the variable (Y1-mean) in the PCOS labeled patients, the mean of the variable (Y0-

mean) in the patients without the PCOS label, and the mean and standard deviation of the variable over all

patients (All-mean and All-SD). Ranking predictor variables by the absolute value of their coefficients in

the logistic regression model amounts to ranking these variables by how much they affect the predicted

probability of the outcome. A positive coefficient implies that the larger the value of the variable within

the range specified by the data, the higher the chance of having a PCOS diagnosis as defined by the model

outcome.

Results

Results of data acquisition and data pre-processing

After inclusion and exclusion criteria were applied to all 65,431 women within the initial data

pool, 30,601 patient records were available for this analysis and defined populations are included in

Figure 1. There were 1,329 patients (4.5%) with a PCOS ICD-9 diagnosis code (Model I). 1,465 patients

had records with PCOM results as present, absent, or unidentifiable. There were 1,056 patients (3.6%)

with undiagnosed PCOS (Model II), and a total of 1,116 (3.8%) of patients with no ICD 256.4 indication

and two out of IM/HA/PCOM positive criteria (Model III). Finally, there were 2,445 PCOS patients

(8.0%) in the combined analysis (Model IV). The total number of records in each model are included in

Supplementary Table 2. In the total cohort, the patients were predominantly Black/African American

(40.3%) and White (26.5%), with an average age of 33.6 years (SD = 6.6). Complete demographic

characteristics are described in Table 1.

There were 43 categorical variables and 12 continuous variables retained as predictors after the

data pre-processing procedures. There were four pairs of highly correlated variables and one variable

from each correlated pair included in the final model as noted in Supplemental Table 5. Supplementary

Table 4 describes all 51 variables used by the predictive models.

Model Performance

Tables 2, 3, 4 and 5 display the parsimonious models that use the MLP score (LR-L2-MLP score) and show the most significant variables in the prediction of the outcome for Models I, II, III, and IV, respectively. All p-values were less than 0.05, which was set as the significance level.

For Model I, the parsimonious predictive model achieved an AUC (SD) of 82.3% (1.7). The MLP score ($\beta = 0.71$) and obesity ($\beta = 0.45$) were positively correlated with PCOS diagnosis. Pregnancy (gravidity $\beta = -0.53$; positive pregnancy test $\beta = -0.50$), normal BMI ($\beta = -0.24$), smoking ($\beta = -0.18$), age ($\beta = -0.16$), and Hispanic race ($\beta = -0.10$) were inversely correlated with PCOS diagnosis as shown in Table 2.

For Model II, the parsimonious predictive model achieved an AUC (SD) of 77.6% (1.3). The MLP score ($\beta = 0.61$), obesity ($\beta = 0.21$), normal BMI ($\beta = 0.15$), normal blood pressure ($\beta = 0.16$), negative pregnancy test ($\beta = 0.12$), and normal HDL ($\beta = 0.08$) were positively correlated with undiagnosed PCOS. Age ($\beta = -0.27$), pregnancy (gravidity $\beta = -0.26$; positive pregnancy test $\beta = -0.19$), and Hispanic race ($\beta = -0.18$) were inversely correlated with undiagnosed PCOS as show in Table 3.

For Model III, the parsimonious predictive model achieved an AUC (SD) of 77.4% (1.6). The MLP score ($\beta = 0.60$), obesity ($\beta = 0.19$), normal blood pressure ($\beta = 0.17$), normal BMI ($\beta = 0.14$), Black race (0.13), negative pregnancy test ($\beta = 0.12$), and normal HDL ($\beta = 0.09$) were positively correlated with undiagnosed PCOS. Age ($\beta = -0.25$), pregnancy (gravidity $\beta = -0.24$; positive pregnancy test $\beta = -0.20$), and Hispanic race ($\beta = -0.15$) were inversely correlated with undiagnosed PCOS as show in Table 4.

For Model IV, the parsimonious predictive model achieved an AUC (SD) of 79.1% (1.1). The MLP score ($\beta = 0.7$), obesity ($\beta = 0.31$), normal BMI ($\beta = 0.15$), hypertension ($\beta = 0.07$) and some higher degree of education, such as college or vocational/technical school ($\beta = 0.06$) were positively correlated with PCOS diagnosis. Age ($\beta = -0.21$), pregnancy (gravidity $\beta = -0.37$; positive pregnancy test $\beta = -0.34$; negative pregnancy test $\beta = -0.05$), Hispanic race ($\beta = -0.12$), and smoking ($\beta = -0.08$) were inversely correlated with PCOS diagnosis as shown in Table 5.

GBT models had the highest performance. Predictions of PCOS in a test set of patients not used

during algorithm training achieved 85%, 81%, 80%, and 82% AUC for Models I, II, III, and IV,

respectively. We also report the performance with the logistic regression model (LR-L1) after SFS and

the performance when using our developed MLP score alongside variables selected via recursive feature

elimination (LR-L2-MLP score). Supplementary Table 6 displays features for each model, associated

with LR-L1 algorithm after SFS. As we hypothesized, developing models using the MLP score (LR-L2-

MLP score) leads to improvement of the performance of linear models (LR-L1) for Models I, II, III, and

IV, respectively from 79%, 72%, 73%, and 75% AUC to 82%, 78%, 77%, and 79% AUC. Table 6 details

the models with the best performance (highest AUC) using all 51 features before and after statistical

feature selection (SFS). In Table 6, the means and standard deviations of AUC and weighted-F1 scores on

the test set over the five repetitions are listed. Supplementary Table 7 displays the performance of all

models and all algorithms, before and after statistical feature selection (SFS).

Discussion

Evaluating an at-risk population for PCOS is essential for early diagnosis and initiating multi-

disciplinary care with the goal of reducing health risks (endometrial hyperplasia/cancer), infertility and

pregnancy complications, and chronic disease burden including cardiometabolic disorders associated with

PCOS. Retrospective analysis of the at-risk population within an urban health center allows for

assessment of factors predictive of diagnosis. Of note, the study sample represents a population of

patients who had any visit to BMC for primary care, obstetrics and gynecology, endocrinology, family

medicine, or general internal medicine and does not represent a random sample. While this is not a

population level assessment, our model is applicable to patients with high suspicion for PCOS who

interact with the healthcare system.

The ranked list of variables, from the most predictive to the least predictive of the PCOS

outcome, informed the main drivers of the predictive models. For example, non-gravidity, high levels of

LH, low levels of FSH, obesity, and higher BMI increase the likelihood of PCOS. These variables are

consistent with key variables from other models and in the pathophysiology of PCOS. The overall

predictive accuracy was high for all models, suggesting that a predictive model may assist in early

detection of PCOS within those at risk in an electronically interfaced medical record. Furthermore, we

found that non-linear models had superior predictive capacity compared to linear models for all four

model outcomes, potentially allowing for inclusion of non-linear reproductive hormone relationships.

347   When assessing patients who received a diagnosis of PCOS (Model I), the most predictive factors

related to diagnosis were hormone levels (as captured by the MLP score) and obesity, a clinical factor in

supporting a PCOS diagnosis. Specifically, there is a non-linear relationship between reproductive

hormones such as FSH, LH, and estradiol. Often these hormonal lab tests are obtained randomly in those

with oligomenorrhea, and it is also common to find an elevated FSH to LH ratio. A concern may also be

the misclassification of hypothalamic amenorrhea into the group classified as PCOS where the FSH and

LH levels would be low or suppressed, or in the setting of premature ovarian insufficiency, notable by an

elevated FSH and low estradiol. The MLP score allows for the diversity of relationships of these hormone

levels and was trained using a neural network to appropriately classify PCOS. Additionally, prior

pregnancy (gravidity) and a positive pregnancy test were negatively associated with a diagnosis of PCOS,

consistent with the underlying increased risk of infertility due to oligo-ovulation which many patients

with PCOS experience. Additionally, normal BMI and smoking, a known ovarian toxicant, were

negatively associated with the presence of a PCOS diagnosis, which may indicate patient characteristics

that increase risk of a delayed PCOS diagnosis. These identified predictor variables demonstrate the

robustness of the model towards predicting phenotypic traits of patients with PCOS, which is aligned with

the performance accuracy. While the significant factors such as hormone levels, gravidity, bHCG, and

obesity identified in the model are already known to be associated with PCOS, the true impact of our

model lies within the implementation of such a tool within the EMR to alert clinicians to the diagnosis

and subsequently allow patients to access necessary healthcare to either prevent or manage co-morbidities

related to PCOS.

When assessing patients who met diagnostic criteria without the ICD-9 label of PCOS (Models II

and III), predictive factors both supported the underlying PCOS diagnosis and alluded towards factors

that may contribute to missing the diagnosis despite meeting Rotterdam criteria. Similar to Model I,

gravidity and a positive pregnancy test were negatively associated with Models II and III diagnosis, while

obesity was positively associated with Models II and III diagnosis, consistent with the PCOS diagnosis

within Model I. Interestingly, distinct positive predictors among Models II and III were normal BMI,

normal blood pressure, and normal HDL. These patients may present as the "lean" phenotype of PCOS or

those with mild features, leading to underdiagnosis of PCOS. Diagnosing "lean" PCOS can be more

nuanced, potentially delaying diagnosis or requiring more specialized consultation (25). By evaluating

key factors among the underdiagnosed population, this predictive model can serve as a safety net among

hospital systems to aid in timely diagnosis and identification of diagnostic barriers through EHR data

analytics. Addressing diagnostic gaps such as PCOS underdiagnosis among the "lean" population can

lead to more timely diagnosis and downstream follow-up for known clinical sequelae associated with

PCOS.

Consistent with Models I, II, and III, positive pregnancy test and gravidity were both negatively

associated with PCOS diagnosis in Model IV while obesity and presence of hypertension were both

positively associated with the Model IV combined PCOS outcome. Some higher degree of education,

such as college or vocational/technical school, was also positively associated with the outcomes of

undiagnosed PCOS and combined PCOS (Models II, III, and IV), which may suggest that education

status and patient's self-advocacy for seeking care within a medical system may be implicated specifically

in under-diagnosed individuals. Of note, we dropped insurance status after finding that the null was a

strong predictor of PCOS, though it is interesting to note that 83% of 331 patients in this dataset with

missing insurance have PCOS. Insurance status alludes to socioeconomic barriers such as financial access

to care, which can result in a delay in timely diagnosis through either inability to seek evaluation or

follow through with testing. Persistence in seeking treatment within a fractionated health care system can

be challenging financially and psychologically, as patients may need multiple evaluation or specialist's

consultation to reach the right diagnosis.

Other predictive models have been created for earlier detection of PCOS as well as for predicting

long-term health outcomes among women with a diagnosis of PCOS. One such model was created from

11,720 ovarian stimulation cycles at Peking University Third Hospital. The model used serum

antimullerian hormone (AMH) and androstenedione levels, BMI, and menstrual cycle length to predict a

diagnosis of PCOS. The algorithm was then developed into an online platform that is able to calculate

one's risk of PCOS given certain indicators that are inputted into the model, allowing for better screening

abilities in the clinic (26). Another study created a similar model, taking into account AMH and BMI to

predict a diagnosis of PCOS or other ovulatory dysfunction disorders among 2,322 women (9). They

found that in women with higher BMIs and lower AMH levels could be used to predict PCOS compared

to normal-weight or underweight women. Deshmukh et al. created a simple four-variable model which

included free androgen index (FAI), 17-hydroxyprogesterone, AMH, and waist circumference for

predicting risk of PCOS in a cross-sectional study involving 111 women with PCOS and 67 women

without PCOS (27). Lastly, Joo et al. used polygenic and phenotypic risk scores to develop a PCOS risk

prediction algorithm (28). They found high degrees of association between PCOS and various metabolic

and endocrine disorders including obesity, type 2 diabetes, hypercholesterolemia, disorders of lipid

metabolism, hypertension, and sleep apnea (28). Our model is unique because it includes a general

hospital-sourced population with a heterogenous population as opposed to solely in the context of fertility

care. Furthermore, the parsimonious and interpretable models were very close in achieving full model

predictive accuracy, performing also relatively closely to the best-performing non-linear models.

Essentially, our parsimonious models "isolate" nonlinearities in hormone levels (captured by the MLP

score) and linearly combine that score with other variables. Our variables are easily accessible in an

electronic health dataset, rendering the models helpful for clinical prediction. However, our study did not

evaluate AMH as a predictive variable because it was not widely utilized during the time window of this

data extraction corresponding with ICD-9 codes.

In addition to the goal of improved screening for PCOS, other models have been created to

predict long-term clinical outcomes in women with PCOS, such as ovulation, conception, and live birth

(10,11). Given the increased risk of insulin resistance in women with PCOS, Gennarelli et al. created a

mathematical model to predict insulin sensitivity based on variables such as BMI, waist and hip

circumferences, truncal-abdominal skin folds, and serum concentrations of androgens, SHBG,

triglycerides, and cholesterol (12). Models to predict non-alcoholic fatty liver disease (NAFLD) risk

among young adults with PCOS have also been generated (29). Combining earlier detection with more

accurate risk stratification of clinical sequalae through predictive modeling can significantly improve the

long-term health outcomes of women with PCOS. Application of our models to predict other down-

stream health risks after the diagnosis of PCOS is a future area of research.

Beyond the long-term health impacts of PCOS, the condition also carries a significant economic

cost for our healthcare system. A study by Riestenberg et al (2022) recently estimated the total economic

burden of PCOS, as well as the cost specifically for pregnancy-related complications and long-term health

morbidities (2). The authors estimated the annual economic burden of PCOS to be $8 billion as of 2020 in

the United States. Furthermore, the excess cost of pregnancy-related comorbidities such as gestational

hypertension, gestational diabetes, and preeclampsia attributable to PCOS totals $375 million USD

annually. Outside of pregnancy, the cost of long-term comorbidities associated with PCOS including

stroke and type 2 diabetes mellitus was estimated at $3.9 billion USD. Meanwhile, the cost for diagnostic

evaluation of PCOS was less than 2% of the total economic burden. This estimated financial burden

suggests that predictive models aiding earlier diagnosis could not only reduce long-term health

consequences of PCOS but also alleviate significant healthcare costs associated with the condition.

Strengths of our model include the large sample size of patients used to generate these predictive

models which are highly accurate and robust in PCOS diagnosis prediction and serve as one of the largest

to date (30). Although not included, we also assessed a multi-imputation method to see if multi-imputing

missing values led to improved accuracy. This method produces similar results, with linear models

becoming slightly worse and non-linear models slightly improving. Therefore, since there was no

considerable improvement in models' performance and, more importantly, multi-imputation ultimately

led to loss of interpretability of the data, it was not justifiable to use multi-imputation in our models.

446   Additionally, utilizing the MLP score in this novel application allowed for non-linear

interpretation of the variables. Most models evaluate reproductive hormones as individual variables

within linear models, which does not account for the high inter- and intra-patient variability. By using

non-linear mapping of the hormone values, we were able to generate a composite variable allowing for a

linear function that correlates with the likelihood of an accurate prediction. While using the MLP score

and incorporating the non-linear relationship between reproductive hormones (FSH, estradiol, LH, and

SHBG) allowed for improved accuracy of each of the models, it can be somewhat cumbersome to

implement in other populations and does not quantify the true correlative relationship between each

individual variable comprising the MLP score.

455   Of note, our models were generated using a population who was at risk for PCOS diagnosis based

on clinical parameters, rather than the entire patient population at BMC. The purpose of this study was to

evaluate the at-risk population and not delineate the presence of PCOS in the population at large, or the

entire population presenting for care—as we would need to perform an evaluation on an unselected

population to determine the prevalence of PCOS (31). Utilizing this at risk PCOS population within a

large urban health center allowed us to focus on identifying gaps in diagnosis. Within our at-risk cohort,

1,116 individuals were identified by the model without the ICD-9 code that met Rotterdam PCOS

diagnostic criteria (Model III), suggesting the predictive value of our models to identify at risk groups

within a large health system and reduce delays in diagnosis. A random population of patients would have

lowered or potentially eliminated any modeling signal and potentially lead to minimal association

indicators for PCOS, significantly limiting predictive power. Clinically, to meet Rotterdam criteria for

PCOS diagnosis, patients would need to undergo clinical work-up including clinical evaluation for

concurrent endocrinopathy, amenorrhea evaluation, androgen testing, and ultrasound, without which

diagnosis would not be assigned. If used clinically, this model would need these key pieces of clinical and

laboratory information to accurately assess patient's PCOS risk, thus justifying our utilization of an at-

risk population for model training purposes.

Informative presence in EHR data is defined as data that is present and informed with respect to

the health outcome, in this case PCOS, as well as behavioral patterns of interaction with healthcare

institutions which may be additionally impacted by marginalization (32). This is an important

consideration for interpreting predictive models using EHR data (32,33). Even among those evaluated, we

were able to extract over 1000 patients who were undiagnosed with PCOS among the population,

suggesting the predictive value of the modelling in identifying diagnosis gaps even among small

populations within a large health system. Additional studies need to be conducted in other patient

populations or unselected community-based populations to validate the use of these models, especially

expanding to the entire population within a health system to evaluate the accuracy of our models. This

novel model is the first use of a machine learning algorithm on a large EHR dataset to assess PCOS risk

and to guide early detection and interventions of PCOS, pregnancy planning, and pre-pregnancy

interventions. If the predicted probability of PCOS is high, facilitating an earlier diagnosis, this may

support earlier access to specialized physicians for both fertility care/family planning along with

preventative care for the cardiovascular and gynecological sequelae of longstanding PCOS.

Acknowledgements

We would like to acknowledge Linda Rosen, the research manager of the Clinical Data Warehouse at the

Boston Medical Center for procuring the dataset, and Alexis Veiga, the research assistant who provided

administrative support for this project.

Author contributions

ZZ performed the analysis and co-wrote the manuscript with a focus on the methods. VJ interpreted the

findings and drafted the initial manuscript. AW conducted a literature review, contributed to

interpretation of data, writing, and editing the manuscript. TW initiated the analytical approach to the

research question. JC curated the initial dataset and reviewed the analysis and manuscript drafts. SM and

ICP designed the study, oversaw analysis, interpretation of the findings, and manuscript drafting and

revision process. All authors met ICJME criteria for authorship.

Data availability

All datasets generated during and/or analyzed during the current study are not publicly available but are

available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

References

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456–88.

2. Riestenberg C, Jagasia A, Markovic D, Buyalos RP, Azziz R. Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences. J Clin Endocrinol Metab. 2022 Jan 18;107(2):575–85.

3. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013 Dec 18;6:1–13.

4. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–58.

5. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339–52.

6. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018;86:33–43.

7. Wekker V, Van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(6):942–60.

8. Xu H, Feng G, Alpadi K, Han Y, Yang R, Chen L, et al. A Model for Predicting Polycystic Ovary Syndrome Using Serum AMH, Menstrual Cycle Length, Body Mass Index and Serum Androstenedione in Chinese Reproductive Aged Population: A Retrospective Cohort Study. Front Endocrinol. 2022;13:821368.

9. Vagios S, James KE, Sacha CR, Hsu JY, Dimitriadis I, Bormann CL, et al. A patient-specific model combining antimüllerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders. Fertil Steril. 2021;115(1):229–37.

10. Kuang H, Jin S, Hansen KR, Diamond MP, Coutifaris C, Casson P, et al. Identification and replication of prediction models for ovulation, pregnancy and live birth in infertile women with polycystic ovary syndrome. Hum Reprod. 2015;30(9):2222–33.

11. Jiang X, Liu R, Liao T, He Y, Li C, Guo P, et al. A Predictive Model of Live Birth Based on Obesity and Metabolic Parameters in Patients With PCOS Undergoing Frozen-Thawed Embryo Transfer. Front Endocrinol. 2021;12.

12. Gennarelli G, Holte J, Berglund L, Berne C, Massobrio M, Lithell H. Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod. 2000;15(10):2098–102.

13. ESHRE TR, Group ASPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

541   14. Cheng JJ, Mahalingaiah S. Data mining polycystic ovary morphology in electronic medical record
542   ultrasound reports. Fertil Res Pract. 2019;5(1):1–7.

543   15. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference and
544   prediction. Vol. 1. Springer series in statistics Springer, Berlin; 2001.

545   16. Chen R, Paschalidis IC. Distributionally Robust Learning. Found Trends® Optim. 2020 Dec 22;4(1–
546   2):1–243.

547   17. Brisimi TS, Xu T, Wang T, Dai W, Adams WG, Paschalidis IC. Predicting Chronic Disease
548   Hospitalizations from Electronic Health Records: An Interpretable Classification Approach. Proc
549   IEEE. 2018 Apr;106(4):690–707.

550   18. Brisimi TS, Xu T, Wang T, Dai W, Paschalidis IC. Predicting diabetes-related hospitalizations based
551   on electronic health records. Stat Methods Med Res. 2019 Dec 1;28(12):3667–82.

552   19. Chen R, Paschalidis ICh. Robust Grouped Variable Selection Using Distributionally Robust
553   Optimization. J Optim Theory Appl. 2022 Sep 1;194(3):1042–71.

554   20. Chen R, Paschalidis IC, Hatabu H, Valtchinov VI, Siegelman J. Detection of unwarranted CT radiation
555   exposure from patient and imaging protocol meta-data using regularized regression. Eur J Radiol Open.
556   2019;6:206–11.

557   21. Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. In: Proceedings of the 22nd ACM
558   SIGKDD International Conference on Knowledge Discovery and Data Mining [Internet]. San
559   Francisco, California, USA: Association for Computing Machinery; 2016 [cited 2020 Jun 19]. p. 785–
560   94. (KDD '16). Available from: https://doi.org/10.1145/2939672.2939785

561   22. Breiman L. Random forests. Mach Learn. 2001;45(1):5–32.

562   23. Ke G, Meng Q, Finley T, Wang T, Chen W, Ma W, et al. Lightgbm: A highly efficient gradient boosting
563   decision tree. Adv Neural Inf Process Syst. 2017;30.

564   24. Saito T, Rehmsmeier M. The Precision-Recall Plot Is More Informative than the ROC Plot When
565   Evaluating Binary Classifiers on Imbalanced Datasets. Brock G, editor. PLOS ONE. 2015 Mar
566   4;10(3):e0118432.

567   25. Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical
568   approach. J Diabetes Metab Disord. 2018 Nov 13;17(2):277–85.

569   26. Xu H, Feng G, Alpadi K, Han Y, Yang R, Chen L, et al. A Model for Predicting Polycystic Ovary
570   Syndrome Using Serum AMH, Menstrual Cycle Length, Body Mass Index and Serum
571   Androstenedione in Chinese Reproductive Aged Population: A Retrospective Cohort Study. Front
572   Endocrinol. 2022;13.

573   27. Deshmukh H, Papageorgiou M, Kilpatrick ES, Atkin SL, Sathyapalan T. Development of a novel risk
574   prediction and risk stratification score for polycystic ovary syndrome. Clin Endocrinol (Oxf).
575   2019;90(1):162–9.

28. Joo YY, Actkins K, Pacheco JA, Basile AO, Carroll R, Crosslin DR, et al. A polygenic and phenotypic
risk prediction for polycystic ovary syndrome evaluated by phenome-wide association studies. J Clin
Endocrinol Metab. 2020;105(6):1918–36.

29. Carreau AM, Pyle L, Garcia-Reyes Y, Rahat H, Vigers T, Jensen T, et al. Clinical prediction score of
nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index).
Clin Endocrinol (Oxf). 2019;91(4):544–52.

30. Shekhar S, Barrera FJ, Brown E, Rojo A, Obeso J, Plata H, et al. Abstract #1413640: Artificial
Intelligence and Machine Learning in the Detection of Polycystic Ovarian Syndrome: A Systematic
Review and Meta-Analysis. Endocr Pract. 2023 May 1;29(5):S88–9.

31. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The Prevalence and Features of
the Polycystic Ovary Syndrome in an Unselected Population. J Clin Endocrinol Metab. 2004 Jun
1;89(6):2745–9.

32. Harton J, Mitra N, Hubbard RA. Informative presence bias in analyses of electronic health records-
derived data: a cautionary note. J Am Med Inform Assoc JAMIA. 2022 Jun 14;29(7):1191–9.

33. Sisk R, Lin L, Sperrin M, Barrett JK, Tom B, Diaz-Ordaz K, et al. Informative presence and observation
in routine health data: A review of methodology for clinical risk prediction. J Am Med Inform Assoc
JAMIA. 2020 Nov 9;28(1):155–66.

Figure 1. Flow of patients from the BMC CDW into the dataset used by the study.

Table 1. Demographic characteristics of the study population and by model.

Variable	Model I	Model II	Model III	Model IV
Age, Mean years (SD)	33.6 (6.6)	33.7 (6.6)	33.7 (6.6)	33.6 (6.6)
Race, n (%)				
Black/African American	11881 (40.3)	11824 (40.5)	11861 (40.5)	12395 (40.5)
White/Caucasian	7812 (26.5)	7733 (26.5)	7741 (26.4)	8086 (26.4)
Hispanic/Latina	2858 (9.7)	2837 (9.7)	2841 (9.7)	2929 (9.6)
Asian	1350 (4.6)	1354 (4.6)	1354 (4.6)	1406 (4.6)
Middle Eastern	175 (0.6)	176 (0.6)	176 (0.6)	184 (0.6)
American Indian/Native American	163 (0.6)	162 (0.6)	162 (0.6)	168 (0.5)
Native Hawaiian/Pacific Islander	17 (0.1)	18 (0.1)	18 (0.1)	18 (0.1)
Other	979 (3.3)	966 (3.3)	966 (3.3)	1023 (3.3)
Unknown	4250 (14.41)	4146 (14.19)	4153 (14.19)	4392 (14.4)
Marital Status				
Single	22325 (75.7)	22155 (75.8)	22199 (75.8)	23224 (75.9)
Married	5833 (19.8)	5753 (19.7)	5767 (19.7)	6018 (19.7)
Separated	392 (1.3)	391 (1.3)	392 (1.3)	401 (1.3)
Divorced	388 (1.3)	379 (1.3)	380 (1.3)	397 (1.3)
Widowed	35 (0.1)	35 (0.1)	35 (0.1)	35 (0.1)
Other	502 (1.7)	489 (1.7)	489 (1.7)	516 (1.7)
Unknown	10 (0.03)	10 (0.03)	10 (0.03)	10 (0.03)
Body Mass Index				
Normal (BMI < 25)	7534 (25.6)	7685 (26.3)	7697 (26.3)	7902 (25.8)
Overweight (BMI between 25-30)	5694 (19.3)	5689 (19.5)	5707 (19.5)	5941 (19.4)
Obese (BMI ≥ 30)	7645 (25.9)	7369 (25.2)	7387 (25.2)	7985 (26.1)
Unknown	8612 (29.2)	8469 (29.0)	8481 (29.0)	8,773 (28.7)

Table 2. Most significant variables for PCOS diagnosis prediction in Model I.

Rank	Variables	β	$\beta - \%95$ CI	Y-correlation	p-value	Y1-mean	Y0-mean	All-mean	All-std
0	MLP Score	0.71	0.028	0.33	6.80E-197	0.17	0.04	0.05	0.08
1	Intercept	-0.68	-	-	-	-	-	-	-
2	Gravidity	-0.53	0.018	-0.12	4.55E-78	1.28	2.08	2.04	1.39

			β - %95 CI	Y-correlation	p-value	Y1-mean	Y0-mean	All-mean	All-std
3	Positive bHCG	-0.5	0.019	-0.09	1.50E-48	0.05	0.23	0.22	0.42
4	Obesity	0.45	0.017	0.11	1.38E-81	0.51	0.27	0.28	0.45
5	Normal BMI	-0.24	0.017	-0.05	3.57E-16	0.15	0.26	0.26	0.44
6	Smoker	-0.18	0.017	-0.03	6.62E-05	0.09	0.14	0.14	0.34
7	Age	-0.16	0.016	-0.08	1.70E-25	31.34	33.79	33.68	6.61
8	Hispanic/Latina Race	-0.1	0.016	-0.02	1.82E-03	0.07	0.10	0.10	0.30

Table 3. Most significant variables for PCOS diagnosis prediction in Model II.

Rank	Variables	β	β - %95 CI	Y-correlation	p-value	Y1-mean	Y0-mean	All-mean	All-std
0	MLP Score	0.61	0.023	0.26	2.13E-142	0.12	0.04	0.04	0.06
1	Intercept	-0.44	-	-	-	-	-	-	-
2	Age	-0.27	0.015	-0.08	2.26E-31	31.01	33.79	33.69	6.61
3	Gravidity	-0.26	0.016	-0.09	2.35E-63	1.42	2.08	2.06	1.39
4	Obesity	0.21	0.016	0.03	9.60E-06	0.34	0.27	0.27	0.44
5	Positive bHCG	-0.19	0.017	-0.06	4.14E-21	0.10	0.23	0.23	0.42
6	Hispanic/Latina Race	-0.18	0.016	-0.02	2.69E-03	0.06	0.10	0.10	0.30
7	Normal BP	0.16	0.015	0.03	1.37E-07	0.60	0.51	0.51	0.50
8	Normal BMI	0.15	0.016	0.03	8.57E-07	0.34	0.26	0.26	0.44
9	Negative bHCG	0.12	0.015	0.06	1.44E-22	0.37	0.23	0.23	0.42
10	HDL	0.08	0.015	0.01	1.03E-10	52.13	51.59	51.61	7.86

Table 4. Most significant variables for PCOS diagnosis prediction in Model III.

Rank	Variables	β	β - %95 CI	Y-correlation	p-value	Y1-mean	Y0-mean	All-mean	All-std
0	MLP Score	0.6	0.023	0.26	7.41E-142	0.10	0.04	0.04	0.05
1	Intercept	-	-	-	-	-	-	-	-
2	Age	-0.25	0.015	-0.08	5.91E-30	31.16	33.79	33.69	6.61
3	Gravidity	-0.24	0.016	-0.09	2.47E-63	1.46	2.08	2.06	1.39
4	Positive bHCG	-0.20	0.017	-0.06	3.59E-20	0.11	0.23	0.23	0.42
5	Obesity	0.19	0.016	0.03	2.73E-06	0.34	0.27	0.27	0.44
6	Normal BP	0.17	0.015	0.04	3.94E-08	0.60	0.51	0.51	0.50

Rank	Variables	β	β - %95 CI	Y-correlation	p-value	Y1-mean	Y0-mean	All-mean	All-std
7	Hispanic/Latina Race	-0.15	0.016	-0.02	2.00E-03	0.06	0.10	0.10	0.30
8	Normal BMI	0.14	0.016	0.03	6.76E-06	0.33	0.26	0.26	0.44
9	Black/African American Race	0.13	0.015	0.02	2.03E-03	0.46	0.40	0.41	0.49
10	Negative bHCG	0.12	0.015	0.06	2.20E-25	0.37	0.23	0.23	0.42
11	HDL	0.09	0.015	0.01	4.06E-12	52.04	51.59	51.61	7.86

Table 5. Most significant variables for PCOS diagnosis prediction in Model IV.

Rank	Variables	β	β - %95 CI	Y-correlation	p-value	Y1-mean	Y0-mean	All-mean	All-std
0	MLP Score	0.7	0.024	0.36	0.00E-01	0.20	0.07	0.08	0.10
1	Intercept	-0.44	-	-	-	-	-	-	-
2	Gravidity	-0.37	0.017	-0.14	2.17E-135	1.36	2.08	2.02	1.39
3	Positive bHCG	-0.34	0.017	-0.10	2.23E-65	0.08	0.23	0.22	0.41
4	Obesity	0.31	0.015	0.10	2.86E-66	0.43	0.27	0.28	0.45
5	Age	-0.21	0.015	-0.10	1.91E-52	31.26	33.79	33.59	6.62
6	Hispanic/Latina Race	-0.12	0.015	-0.03	2.34E-06	0.07	0.10	0.10	0.29
7	Smoker	-0.08	0.015	-0.02	3.00E-04	0.11	0.14	0.14	0.34
8	Hypertension	0.07	0.015	0.04	3.63E-12	0.28	0.21	0.22	0.41
9	Education – Some College/Technical/ Vocational School	0.06	0.014	0.03	1.55E-04	0.18	0.15	0.15	0.36
10	Negative bHCG	-0.05	0.015	0.05	2.29E-16	0.31	0.23	0.24	0.42

Table 6. Model performance over the test set, in the format of mean percentage (SD percentage) over 5 repetitions.

	Model I		Model II		Model III		Model IV	
	AUC	F1-weighted	AUC	F1-weighted	AUC	F1-weighted	AUC	F1-weighted
Best full models before SFS	XGBoost (51 features)		XGBoost (51 features)		XGBoost (51 features)		XGBoost (51 features)	
	85.2 (1.8)	94.5 (0.2)	80.6 (0.5)	95.1 (0.2)	80.4 (0.7)	94.8 (0.1)	81.8 (1.4)	91.1 (0.4)
Best full models after SFS	XGBoost (14 features)		XGBoost (16 features)		XGBoost (17 features)		XGBoost (17 features)	
	83.6 (1.7)	94.5 (0.2)	80.5 (0.7)	95.1 (0.2)	79.8 (1.1)	94.8 (0.1)	81.1 (1.3)	90.9 (0.3)

LR-L1 (14 features)		LR-L1 (16 features)		LR-L1 (17 features)		LR-L1 (17 features)	
79.2 (1.9)	93.9 (0.2)	71.7 (0.9)	94.7 (0.1)	72.9 (2.1)	94.4 (0.1)	74.8 (1.1)	89.7 (0.3)
Parsimonious models LR-L2-MLP score (8 features)		Parsimonious models LR-L2-MLP score (10 features)		Parsimonious models LR-L2-MLP score (11 features)		Parsimonious models LR-L2-MLP score (10 features)	
82.3 (1.7)	94.5 (0.1)	77.6 (1.3)	95.1 (0.1)	77.4 (1.6)	94.9 (0.1)	79.1 (1.1)	90.8 (0.3)